Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

Robert J. Motzer, Ashok Rakhit, Lawrence H. Schwartz, +6

PubMed

ImmunologyImmunoeditingPharmacotherapyMetronomic ChemotherapyImmunotherapy +14

Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.

Ronald M. Bukowski, Patricia Rayman, Robert G. Uzzo, +9

PubMed

Renal PathologyImmunologyPathologyRelative LevelsImmunotherapy +15

Phase II Trial of Liposomal Doxorubicin (Doxil®) in Advanced Soft Tissue Sarcomas

Tarek Chidiac, G. Thomas Budd, Robert Pelley, +9

Investigational New Drugs

Phase Ii TrialMedicineMetronomic TherapyPathologyLiposomal Doxorubicin +3

T-cell adoptive immunotherapy of metastatic renal cell carcinoma

Gregory E. Plautz, Ronald M. Bukowski, Andrew C. Novick, +7

Urology

Tumor ImmunologyCancer ImmunosurveillanceGenitourinary CancerImmunologyT-cell Adoptive Immunotherapy +5

Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma

William Grubb, Lee Ponsky, Simon S. Lo, +8

Radiotherapy and Oncology

UrologySurgical OncologyRadiation TherapyMedicineDose Escalation Protocol +6

Phase II Trial of Interleukin-2 and Interferon-ce in Patients with Renal Cell Carcinoma: Clinical Results and Immunologic Correlates of Response

Ronald M. Bukowski, Thomas Olencki, Qm Wan, +11

Journal of Immunotherapy

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma.

E Wos, T Olencki, Laurie Tuason, +6

PubMed

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

Edward J. Wos, Thomas Olencki, Laurie Tuason, +6

Cancer

Antitumor ActivityRenal PathologyImmunologyImmunotherapeuticsMetronomic Chemotherapy +17

Immunomodulatory Effects of Recombinant Interleukin-3 Treatment on Human Alveolar Macrophages and Monocytes

Mary Jane Thomassen, Joyce Antal, Mary J. Connors, +6

Journal of Immunotherapy

Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.

Ronald M. Bukowski, Thomas Olencki, H Gunn, +10

PubMed

ImmunologyImmunoeditingPharmacotherapyMetronomic ChemotherapyImmunotherapy +19